Active surveillance for low-risk prostate cancer

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3683-3692

  Mazzucchelli, Roberta ^a   Nesseris, Ioannis ^a,b   Cheng, Liang ^c   Lopez Beltran, Antonio ^d   Montironi, Rodolfo ^a   Scarpelli, Marina ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF IOANNINA   (Greece)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Active surveillance; Prostate cancer; Review; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANXIETY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RISK; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HUMAN; NUCLEAR MAGNETIC RESONANCE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; ULTRASOUND; CANCER STAGING; MALE; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTOR;

HUMANS; MALE; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77958517538     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Etzioni R, Penson DF, Legier JM, di Tommaso D, Boer R, Gann PH and Feuer EJ: Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 94: 981-990, 2002. (Pubitemid 34814727)
2. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A and Adami HO: Natural history of early, localized prostate cancer. JAMA 291: 2713-2719, 2004.
3. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG and Schröder F: Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 55: 1321-1330, 2009.
4. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr. Wallace ME, Kantoff PW and Carroll PR: Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112: 1650-1659, 2008.
5. Parker C: Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5: 101-106, 2004.
6. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA and Yang N: Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II. Radical prostatectomy-treated patients. J Urol 141: 1076-1083, 1989.
7. Schmid HP, McNeal JE and Stamey TA: Clinical observations on the doubling time of prostate cancer. Eur Urol 23: 60-63, 1993.
8. Parker CC and Dearnaley DP: The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol 49: 103-110, 1998. (Pubitemid 29017904)
9. Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA and Taylor JM: Overall survival after prostate-specific antigen-detected recurrence following conformai radiation therapy. Int J Radiat Oncol Biol Phys 48: 629-633, 2000.
10. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO and Johansson JE: Scandinavian Prostate Cancer Group Study Number 4: Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100: 1144-1154, 2008.
11. Epstein JI, Walsh PC, Carmichael M and Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271: 368-374, 1994.
12. Epstein JI, Chan DW, Sokoll LF, Walsh PC, Cox JL, Rittenhouse H, Wolfen R and Carter HB: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160: 2407-2411, 1998.
13. Bastian PJ, Mangold LA, Epstein JI and Partin AW: Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101: 2001-2005, 2004.
14. Jeldres C, Suardi N, WaIz J, Hutterer GC, Ahyai S, Lattouf JB, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H and Karakiewicz PI: Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 54: 1306-1313, 2008.
15. Chun FK, Haese A, Ahyai SA, Walz J, Suardi N, Capitanio U, Graefen M, Erbersdobler A, Huland H and Karakiewicz PI: Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 113: 701-709, 2008.
16. Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN and Koch MO: Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol 174: 898-902, 2005.
17. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW and Carroll PR: Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112: 1650-1659, 2008.
18. D'Amico AV, Cote K, Loffredo M, Renshaw AA and Schultz D: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20: 4567-4573, 2002.
19. Graefen M, Ahyai S, Heuer R, Salomon G, Schlomm T, Isbarn H, Budäus L, Heinzer H and Huland H: Active surveillance for prostate cancer. Urologe A 47: 261-269, 2008.
20. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T and Scardino PT: An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 171:1520-1524, 2004.
21. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B and Manoharan M: Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 101: 165-169, 2008.
22. Van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA, Horwich A, Dearnaley DP and Parker CC: Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 54: 1297-1305, 2008.
23. Van den Bergh RCN, Roemeling S, Roobol MJ, Roobol W, Schroder FH and Bangma CH: Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52: 1560-1563, 2007.
24. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat SF, Slawin KM and Ohori M: Counseling men with prostate cancer: a nomogramfor predicting the presence of small, moderately differentiated, confined tumors. J Urol 170: 1792-1797, 2003.
25. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ and Schröder FH: Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177: 107-112, 2007.
26. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS and Carroll PR: The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22: 2141-2149, 2004.
27. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH and de Koning HJ: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 95: 868-878, 2003. (Pubitemid 36833878)
28. Albertsen PC, Hanley JA and Fine J: 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095-2101, 2005.
29. Capitanio U, Jeldres C, Shariat SF and Karakiewicz P: Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best. Eur Urol 54: 958-959, 2008.
30. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI and Partin AW: Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69: 1095-1101, 2007.
31. Nakanishi H, Wang X, Ochiai A, Trpkov K, Yilmaz A, Donnelly JB, Davis JW, Troncoso P and Babaian RJ: A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer 110: 2441-2447, 2007.
32. Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ and Schröder FH: Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51: 1244-1251, 2007.
33. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974, 1998. (Pubitemid 28445094)
34. Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou CC and de la Taille A: Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance -does the risk of misclassification vary according to biopsy criteria? J Urol 183: 539-544, 2010.
35. Sanda MG and Kaplan ID: A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA 301: 2141-2151, 2009.
36. Smaldone MC, Cowan JE, Carroll PR and Davies BJ: Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol 183: 138-143, 2010.
37. Thaxton CS, Loeb S, Roehl KA, Kan D and Catalona WJ: Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols. Urology 75: 414-418, 2010.
38. Tseng KS, Landis P, Epstein JI, Trock BJ and Carter HB: Risk stratification of men choosing surveillance for low-risk prostate cancer. J Urol 183: 1779-1785, 2010.
39. Ploussard G, Xylinas E, Salomon L, Allory Y, Vordos D, Hoznek A, Abbou CC and de la Taille A: The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol 56: 891-898, 2009.
40. Carter HB, Walsh PC, Landis P and Epstein JI: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 167: 1231-1234, 2002.
41. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC and Epstein JI: Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178: 2359-2364, 2007.
42. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA and Carroll PR: Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112: 2664-2670, 2008.
43. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, and Dearnaley D: Early outcomes of active surveillance for localized prostate cancer. BJU Int 95: 956-960, 2005. (Pubitemid 40655686)
44. Klotz L: Active surveillance for prostate cancer: for whom? J Clin Oncol 25: 8165-8169, 2005.
45. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP and Zattoni F: European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 53: 68-80, 2008.
46. D'Amico AV, Chen MH, Roehl KA and Catalona WJ: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125-135, 2004.
47. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ and Metter EJ: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98: 1521-1527, 2006.
48. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC and Partin AW: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439, 2005. (Pubitemid 41124175)
49. Khatami A, Aus G, Damber JE, Lilja H, Lodding P and Hugosson J: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120: 170-174, 2007.
50. Van As NJ and Parker CC: Active surveillance with selective radical treatment for localized prostate cancer. Cancer J 13: 289-294, 2007.
51. Klotz L: Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nat Clin Pract Urol 2: 136-142, 2005.
52. Klotz L: Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 24: 46-50, 2006.
53. Zietman AL, Thakral H, Wilson L and Schellhammer P: Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 166: 1702-1706, 2001.
54. Stephenson AJ, Jones JS, Hernandez AV, Ciezki JP, Gong MC and Klein EA: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol 55: 610-616, 2009.
55. Ercole B, Marietti SR, Fine J and Albertsen PC: Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol 180: 1336-1339, 2008.
56. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackmaan S and Moul JW: Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21: 4001-4008, 2003.
57. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP and Carroll PR: Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol 170: 2279-2283, 2003.
58. Warlick C, Trock B, Landis P, Epstein J and Carter H: Delayed vs. immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98: 355-357, 2006.
59. Klotz LH and Nam RK: Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis. Can J Urol 13: 48-55, 2006.
60. Gravas S and de Reijke T: Is focal therapy an alternative to active surveillance? J Endourol 2010.
61. Nelson WG, De Marzo AM and Isaacs WB: Prostate cancer. N Engl J Med 349: 366-381, 2003.
62. Shariat SF and Karakiewicz PI: Perspectives on prostate cancer biomarkers. Eur Urol 54: 8-10, 2008.
63. Feinberg AP and Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92, 1983.
64. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB and Nelson WG: Cytidine methylation of regulatory sequences near the pi-class glutathione 5-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91: 11733-11737, 1994.
65. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW and Nelson WG: Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11: 4037-4043, 2005.
66. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE and Rubin MA: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26: 4596-4599, 2007.
67. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP and Schalken JA: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54: 1081-1088, 2008.
68. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H and Babaian RJ: PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179: 1804-1809, 2008.
69. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H and Groskopf J: PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179: 1587-1592, 2008.
70. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB and Sokoll LJ: Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 183: 534-538, 2010.
71. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr. and Terris MK: SEARCH Database Study Group: Delay of radical prostatectomy and risk of biochemical progression in men with low-risk prostate cancer. J Urol 175: 1298-1302, 2006. (Pubitemid 43312973)